MX2023004799A - Formas de estado solido de inhibidor de hdac. - Google Patents
Formas de estado solido de inhibidor de hdac.Info
- Publication number
- MX2023004799A MX2023004799A MX2023004799A MX2023004799A MX2023004799A MX 2023004799 A MX2023004799 A MX 2023004799A MX 2023004799 A MX2023004799 A MX 2023004799A MX 2023004799 A MX2023004799 A MX 2023004799A MX 2023004799 A MX2023004799 A MX 2023004799A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- hdac inhibitor
- state forms
- inhibitor solid
- quinolin
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- QRGHOAATPOLDPF-UHFFFAOYSA-N 2-[6-[(6-fluoroquinolin-2-yl)methylamino]-3-azabicyclo[3.1.0]hexan-3-yl]-n-hydroxypyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CC(C2NCC=3N=C4C=CC(F)=CC4=CC=3)C2C1 QRGHOAATPOLDPF-UHFFFAOYSA-N 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a la sal de Forma 1 de mesilato cristalino N-hidroxi 2-{6-[(6-fluoro-quinolin-2-ilmetil)- amino]-3-aza-biciclo[3.1.0]hex-3-il}pirimidina-5-carboxamida y métodos para fabricar la misma. La sal de Forma 1 de mesilato cristalino N-hidroxi 2-{6-[(6-fluoro-quinolin-2-ilmetil)-amino]-3- aza-biciclo[3.1.0]hex-3-il}pirimidina-5-carboxamida es útil en la preparación de composiciones farmacéuticas y formas de dosificación para el tratamiento de cáncer, trastornos inmunitarios e inflamación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106811P | 2020-10-28 | 2020-10-28 | |
| PCT/US2021/057106 WO2022094122A1 (en) | 2020-10-28 | 2021-10-28 | Hdac inhibitor solid state forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004799A true MX2023004799A (es) | 2023-05-10 |
Family
ID=81384331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004799A MX2023004799A (es) | 2020-10-28 | 2021-10-28 | Formas de estado solido de inhibidor de hdac. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20230382888A1 (es) |
| EP (1) | EP4237409A4 (es) |
| JP (1) | JP2024503180A (es) |
| KR (1) | KR20230097098A (es) |
| CN (1) | CN116648449A (es) |
| AU (1) | AU2021368107A1 (es) |
| CA (1) | CA3196385A1 (es) |
| IL (1) | IL302289A (es) |
| MX (1) | MX2023004799A (es) |
| TW (1) | TW202233595A (es) |
| WO (1) | WO2022094122A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113694A1 (en) | 2019-12-05 | 2021-06-10 | Viracta Therapeutics, Inc. | Hdac inhibitor solid state forms |
| KR20230097098A (ko) | 2020-10-28 | 2023-06-30 | 비락타 서브시디어리 인크. | Hdac 억제제 고체 상태 형태 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510204D0 (en) * | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
| WO2018013975A1 (en) * | 2016-07-15 | 2018-01-18 | Viracta Therapeutics, Inc. | Hdac inhibitors for use with nk cell based therapies |
| US20200368280A1 (en) | 2018-01-12 | 2020-11-26 | Viracta Therapeutics, Inc. | Epigenetic modifiers for use in cellular immunotherapy |
| TWI813666B (zh) | 2018-04-20 | 2023-09-01 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 一種多功能化合物、其製備方法及其在醫藥上的應用 |
| WO2020243326A1 (en) | 2019-05-31 | 2020-12-03 | Viracta Therapeutics, Inc. | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| WO2021071809A1 (en) | 2019-10-07 | 2021-04-15 | Viracta Therapeutics, Inc. | Dosages for hdac treatment with reduced side effects |
| WO2021113694A1 (en) | 2019-12-05 | 2021-06-10 | Viracta Therapeutics, Inc. | Hdac inhibitor solid state forms |
| KR20230097098A (ko) | 2020-10-28 | 2023-06-30 | 비락타 서브시디어리 인크. | Hdac 억제제 고체 상태 형태 |
| EP4373525A1 (en) | 2021-07-21 | 2024-05-29 | Viracta Subsidiary, Inc. | Cancer treatment combinations |
-
2021
- 2021-10-28 KR KR1020237017672A patent/KR20230097098A/ko unknown
- 2021-10-28 AU AU2021368107A patent/AU2021368107A1/en active Pending
- 2021-10-28 IL IL302289A patent/IL302289A/en unknown
- 2021-10-28 MX MX2023004799A patent/MX2023004799A/es unknown
- 2021-10-28 US US18/034,296 patent/US20230382888A1/en active Pending
- 2021-10-28 TW TW110140165A patent/TW202233595A/zh unknown
- 2021-10-28 JP JP2023525959A patent/JP2024503180A/ja active Pending
- 2021-10-28 CN CN202180088245.2A patent/CN116648449A/zh active Pending
- 2021-10-28 WO PCT/US2021/057106 patent/WO2022094122A1/en active Application Filing
- 2021-10-28 CA CA3196385A patent/CA3196385A1/en active Pending
- 2021-10-28 EP EP21887546.6A patent/EP4237409A4/en active Pending
-
2022
- 2022-12-13 US US18/080,570 patent/US11760748B2/en active Active
-
2023
- 2023-08-02 US US18/364,074 patent/US12012396B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11760748B2 (en) | 2023-09-19 |
| CA3196385A1 (en) | 2022-05-05 |
| US20230159499A1 (en) | 2023-05-25 |
| JP2024503180A (ja) | 2024-01-25 |
| EP4237409A4 (en) | 2024-08-28 |
| WO2022094122A1 (en) | 2022-05-05 |
| US20240166628A1 (en) | 2024-05-23 |
| AU2021368107A1 (en) | 2023-06-22 |
| KR20230097098A (ko) | 2023-06-30 |
| TW202233595A (zh) | 2022-09-01 |
| IL302289A (en) | 2023-06-01 |
| AU2021368107A9 (en) | 2024-10-03 |
| EP4237409A1 (en) | 2023-09-06 |
| US20230382888A1 (en) | 2023-11-30 |
| US12012396B2 (en) | 2024-06-18 |
| CN116648449A (zh) | 2023-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004799A (es) | Formas de estado solido de inhibidor de hdac. | |
| MX2016006901A (es) | Forma cristalina i de ibrutinib. | |
| PH12020550216A1 (en) | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors | |
| MX2020009957A (es) | Compuestos para el tratamiento de enfermedad de hungtinton. | |
| EP4230623A3 (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| PH12019502033A1 (en) | Pharmaceutical composition comprising selexipag | |
| MX2024001201A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con agonistas de glp-1 para usarse en tratar enfermedades del higado graso. | |
| BR112012021337A8 (pt) | formulações de apixaban. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| TN2012000316A1 (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
| PH12015502630A1 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| MX2022006741A (es) | Formas de estado solido del inhibidor de hdac. | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| MX2024007058A (es) | Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer. | |
| MX2024005429A (es) | Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso. | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| MX2015015200A (es) | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos. | |
| MX2023000198A (es) | Inhibidores de atr y usos de estos. | |
| SG11201902588PA (en) | N3-Cyclically Substituted Thienouracils And Use Thereof | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| EA201990129A1 (ru) | Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона | |
| MX2020001199A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| MX2023006086A (es) | Métodos para prevenir, retrasar o aliviar enfermedades atópicas. | |
| MX2022009851A (es) | Compuestos útiles para inhibir la cetohexocinasa y métodos para elaborarlos y utilizarlos. |